Documentos relacionados

1. Adequancy of treatment with canaglifozin alter alerts pharmacovigilance in the health management area.
2. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
3. Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis.
4. Equipo multidisciplinar de atención al paciente crítico: ¿qué aporta la integración del farmacéutico?
5. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
6. Pharmacokinetics and bioequivalence of two oral formulations of canagliflozin after single-dose administration in healthy Chinese subjects
.
7. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.
8. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.
9. Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
10. Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS.